The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from GlobeNewswire (a Nasdaq OMX company)

Prothena to Report Fourth Quarter and Full Year 2012 Financial Results and Host Webcast and Conference Call on March 28, 2013

Thursday, March 21, 2013

Prothena to Report Fourth Quarter and Full Year 2012 Financial Results and Host Webcast and Conference Call on March 28, 201313:05 EDT Thursday, March 21, 2013DUBLIN, Ireland, March 21, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that it will report its fourth quarter and full year 2012 financial results on Thursday, March 28, 2013, after the close of the U.S. financial markets.  The announcement will be followed by a conference call and live audio webcast at 4:30 p.m. EDT. The conference call and live audio webcast can be accessed as follows: Dial-in:  (877) 312-5854 (U.S. toll free) or (408) 774-4003 (international) Conference ID Number:  24106806 Webcast:  http://ir.prothena.com A replay of the webcast will be available until April 4, 2013 via dial-in to (855) 859-2056 (U.S. toll free) or (404) 537-3406 (international), Conference ID Number 24106806, or via webcast on the investor relations section of Prothena's website at http://ir.prothena.com.About Prothena Prothena Corporation plc (Nasdaq:PRTA) is a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion, particularly on the discovery and development of potential therapeutic monoclonal antibodies directed specifically to disease-causing proteins. These potential therapies have a broad range of indications, including AL and AA forms of amyloidosis, Parkinson's disease and related synucleinopathies, and novel cell adhesion targets involved in inflammatory disease and metastatic cancers. For more information, please visit www.prothena.com.CONTACT: Anita Kawatra Prothena Corporation 646-256-5116 anita.kawatra@prothena.com